|1.||Flora, S J S: 4 articles (07/2013 - 01/2003)|
|2.||Flora, Swaran J S: 4 articles (07/2007 - 02/2004)|
|3.||Kushwaha, Pramod: 2 articles (04/2014 - 12/2012)|
|4.||Yadav, Abhishek: 2 articles (04/2014 - 12/2012)|
|5.||Mehta, Ashish: 2 articles (07/2007 - 02/2004)|
|6.||Kannan, Gurusamy M: 2 articles (04/2006 - 02/2004)|
|7.||Mathur, Rashi: 1 article (04/2014)|
|8.||Flora, Swaran Jeet Singh: 1 article (04/2014)|
|9.||Pathak, Uma: 1 article (04/2014)|
|10.||Samim, Mohammed: 1 article (04/2014)|
09/16/2005 - "Based on these results and in particular higher metal decorporation from blood and brain, we suggest MiADMSA to be a potential drug of choice for the treatment of chronic arsenic poisoning. "
01/01/2003 - "The treatment with MiADMSA although, produced essential metals imbalance which could be a restrictive factor for the possible therapeutic use of this compound in chronic arsenic poisoning and thus require further exploration."
07/01/2013 - "To address this problem, therapeutic efficacy of monoisoamyl meso-2,3-dimercaptosuccinic acid (MiADMSA), an analog of DMSA having lipophilic character, was examined against chronic arsenic poisoning in rats. "
04/01/2006 - "Based on these data, a proposal can be made that greater effectiveness in chelation treatment against chronic arsenic poisoning (i.e., turnover in the oxidative stress and removed of arsenic from the system) could be achieved by combined administration of an antioxidant (preferably having a thiol moiety) with MiADMSA."
07/01/1995 - "The efficacy of four newly synthesized monoesters of meso-2,3-dimercaptosuccinic acid (DMSA), mono-i-amyl- (Mi-ADMS), mono-n-amyl- (Mn-ADMS), mono-i-butyl- (Mi-BDMS), and mono-n-butyl-meso-2,3-dimercaptosuccinate (Mn-BDMS) in increasing survival and arsenic elimination in experimental arsenic poisoning was investigated. "
|2.||Body Weight (Weight, Body)
12/01/2012 - "Animals were exposed to 0.1% lead in drinking water for 16 weeks and then treated with either MiADMSA at 50mg/kg body weight, or monensin at 10mg/kg, or both in combination for a period of 5 days was administered. "
07/01/2013 - "Adult male Wistar rats were orally exposed to arsenic (2mg sodium arsenite/kg body weight) for 10 weeks followed by treatment with MiADMSA (50mg/kg, orally, once daily for 5 consecutive days). "
09/01/1993 - "The chelators DMSA or Mi-ADMS were also administered intraperitoneally, twice, on two consecutive days, in doses of 0.25 mmol/kg body weight as early (0.5 and 24 h) or delayed treatment (24 and 48 h, or 48 and 72 h) after 203Hg administration. "
|4.||Nervous System Diseases (Neurological Disorders)
|5.||Mercury Poisoning (Poisoning, Mercury)
|1.||Succimer (Dimercaptosuccinic Acid)
|8.||Edetic Acid (EDTA)